Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
तुलना करने के लिए मीट्रिक्स | CING | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधCINGपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −3.1x | −2.4x | −0.4x | |
PEG अनुपात | −0.05 | −0.04 | 0.00 | |
क़ीमत/बुक | 27.7x | 1.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 1.7x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 209.7% | 50.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 8.7% | 5.9% | अनलॉक करें |